Spero Therapeutics to Present at Upcoming November Investor Conferences
November 01 2023 - 4:05PM
Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset
clinical-stage biopharmaceutical company, focused on identifying,
developing and commercializing treatments in high unmet need areas
involving rare diseases and multi-drug resistant (MDR) bacterial
infections, today announced that Sath Shukla, President and Chief
Executive Officer, will be available for one-on-one meetings at the
Truist Securities BioPharma Symposium, to be held at the Lotte New
York Palace in New York, NY, on November 8-9, 2023 and will present
and be available for one-on-one meetings at the 6th Annual Evercore
ISI HealthCONx Conference to be held at the Kimpton EPIC Miami
Hotel in Miami, FL, on November 28-30, 2023. Details are as
follows:
Truist Securities BioPharma
Symposium Investor One-on-One Meetings:
Wednesday, November 8, 2023, from 8AM-5PM ET
6th Annual
Evercore ISI HealthCONx Conference Analyst
Fireside Chat: Tuesday, November 28, 2023, from
7:55AM-8:15AM ET Webcast Link:
https://wsw.com/webcast/evercore39/spro/2409596
The webcast for the Evercore ISI event may also
be accessed through Spero Therapeutics’ website
(www.sperotherapeutics.com) on the “Events and Presentations” page
under the “Connect” tab. Replays will be available on the website
following the conclusion of each event.
About Spero TherapeuticsSpero
Therapeutics, headquartered in Cambridge, Massachusetts, is a
multi-asset, clinical-stage biopharmaceutical company focused on
identifying, developing, and commercializing novel treatments for
bacterial infections, including multi-drug resistant bacterial
infections and rare diseases.
- Spero Therapeutics is
developing SPR720 as a novel oral therapy candidate for the
treatment of a rare, orphan pulmonary disease caused by
non-tuberculous mycobacterial infections.
- Tebipenem HBr is an investigational drug in the United States
being developed for the treatment of cUTI, including
pyelonephritis, caused by certain bacteria, in adult patients who
have limited treatment options; tebipenem HBr is not
FDA-approved.
- Spero Therapeutics also has an IV-administered next generation
polymyxin product candidate, SPR206, developed from its potentiator
platform, which is in development to treat multi-drug resistant
Gram-negative infections in the hospital setting.
For more information,
visit https://sperotherapeutics.com.
Forward Looking Statements
This press release may contain forward-looking statements. These
statements include, but are not limited to, statements about the
design, initiation, timing, progress and results of Spero's
preclinical studies and clinical trials and its research and
development programs, as well as the regulatory path forward for
tebipenem HBr and potential FDA approval, and management's
assessment of the results of such preclinical studies and clinical
trials. In some cases, forward-looking statements can be identified
by terms such as "may," "will," "should," "expect," "plan," "aim,"
"anticipate," "could," "intent," "target," "project,"
"contemplate," "believe," "estimate," "predict," "potential" or
"continue" or the negative of these terms or other similar
expressions. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including whether tebipenem HBr, SPR720 and
SPR206 will advance through the clinical trial process on a timely
basis, or at all, taking into account the effects of possible
regulatory delays, slower than anticipated patient enrollment,
manufacturing challenges, clinical trial design and clinical
outcomes; whether the results of such trials will warrant
submission for approval from the FDA or equivalent foreign
regulatory agencies; whether the FDA will ultimately approve
tebipenem HBr and, if so, the timing of any such approval; whether
the FDA will require any additional clinical data or place labeling
restrictions on the use of tebipenem HBr that would delay approval
and/or reduce the commercial prospects of tebipenem HBr; whether a
successful commercial launch can be achieved and market acceptance
of tebipenem HBr can be established; whether results obtained in
preclinical studies and clinical trials will be indicative of
results obtained in future clinical trials; Spero's reliance on
third parties to manufacture, develop, and commercialize its
product candidates, if approved; Spero’s need for additional
funding; the ability to commercialize Spero's product candidates,
if approved; Spero's ability to retain key personnel; Spero’s
ongoing leadership transitions; whether Spero's cash resources will
be sufficient to fund its continuing operations for the periods
and/or trials anticipated; and other factors discussed in the "Risk
Factors" set forth in filings that Spero periodically makes with
the SEC. The forward-looking statements included in this press
release represent Spero's views as of the date of this press
release. Spero anticipates that subsequent events and developments
will cause its views to change. However, while Spero may elect to
update these forward-looking statements at some point in the
future, it specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Spero's views as of any date subsequent to the date of
this press release.
Investor Relations Contact:Ted JenkinsVice
President, Head of Investor RelationsTjenkins@sperotherapeutics.com
(617) 798-4039
Media Inquiries:Lora Grassilli, Health Media
RelationsZeno Grouplora.grassilli@zenogroup.com646-932-3735
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Apr 2024 to May 2024
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From May 2023 to May 2024